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Introduction
Oral cancer is a significant threat to public health all
over the world, especially in South and Southeast Asia,
where betel use is very popular. In Taiwan, it accounts
for an average of 1,436 deaths annually, being the 5th
highest cause of death owing to its malignancy.1 Despite
advances in the detection and treatment of many other
malignancies, the overall survival rate of oral cancer has
remained disappointingly low for the last 10 years and
was reported as less than 50% in the literature.2 Not
surprisingly, this reflects the fact that the treatment
outcome depends not mainly on the improvement of
surgical techniques but on the characteristics of the
cancer itself. According to recent statistical data
reported in Taipei Veterans General Hospital in Taiwan,
the 5-year survival rate of stage I oral cancer patients
was 66.2%, while for stage IV, the survival rate
declined to only 22.2%.3 The paper suggested that
the early detection of oral cancers and treating
patients in their early stages were the most important
factors in improving the survival rate.
Periodic clinical examination of the oral cavity is
the mainstay for early detection of oral cancers. It was
shown to reduce mortality from oral cancer by 32% in
high-risk individuals.4 Additionally, using adjunctive
aids such as toluidine blue (also referred to as tolo-
nium chloride) has been widely accepted to improve
the effectiveness in large-scale screening for oral cancer
diagnosis.5–8 However, it is hazardous if swallowed,
and was shown to have toxicity to fibroblasts. Another
kind of dye material, methylene blue, has a similar
chemical structure and exhibits similar physicochemical
properties to toluidine blue. It is less toxic to the human
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body and has recently been proposed for screening
some gastrointestinal or prostate tumors. The applica-
tion of this material in detecting oral lesions has so far
not been addressed. The objective of this study was to
evaluate the sensitivity and reliability of in vivo staining
with methylene blue as a diagnostic adjunct in screening
for oral malignant or precancerous lesions.
Methods
Subjects
This project was approved by the institutional review
board of Taipei Veterans General Hospital (VGH),
with informed consent signed by patients. Fifty-eight
patients at the Oral and Maxillofacial Surgery, Depart-
ment of Dentistry, Taipei-VGH between October
2002 and August 2003 with the presence of abnormal
oral manifestations were included in this study. All the
patients had no history of oral cancer or previous oral
surgery. The patients’ clinical profiles such as gender,
age, and habits of betel use were collected. All the
patients were subjected to a systematic oral examina-
tion with clinical diagnosis as: (1) homogeneous leu-
koplakia: white, uniform, flat lesion with a smooth,
wrinkled, or corrugated surface, not able to be scraped;
(2) nonhomogeneous leukoplakia: white lesion with
irregular and exophytic surface; (3) erythroplakia: red
lesion with ill-defined margin; (4) ulceration: localized
and superficial lesion that does not heal after local
treatment. The control group comprised 20 dental
students from National Yang-Ming University who
volunteered and who were randomly enrolled, with 
a mean age of 22 years. All volunteer students had 
no habits of betel quid chewing, smoking, or alcohol
drinking.
Gargling solution
A set of methylene blue dye system includes 2 bottles
of solution. The dye rinse solution (Bottle A) contains
active ingredient methylene blue 1%, with the addition
of 1% malachite, 0.5% eosin, glycerol, and dimethylsul-
foxide. Pre- and post-rinse solution (Bottle B) contains
1% lactic acid, raspberry flavor, and purified water.
Staining procedure
The application of methylene blue was as follows. 
A 5-minute teeth brushing procedure was required
before testing. All patients rinsed their mouths with
Bottle B for 20 seconds to remove food debris and
excess saliva and to provide a consistent oral environ-
ment. The mucosa of the target area was gently dried
with gauze and power air spray to ensure that the
lesion was not contaminated with saliva. Patients gar-
gled and rinsed with 1% methylene blue dye (Bottle A)
for 20 seconds, then expectorated. Patients then rinsed
again with Bottle B for 20 seconds to wash out the
excess dye. The pattern of dye retention was assessed
by the intensity of stain retention on the lesion. Local,
stippled, patchy and deep blue stains were marked as
positive (+) reaction. Wide, shallow or faint blue stains
were marked as negative (–) reaction. For equivocal
staining, Bottle B solution was applied with cotton
rolls to wipe out the staining surface. If the blue stain
was washed out, negative reaction was recorded and
vice versa. If the patient had a highly suspicious lesion
that was not all stained by the solution, the patient was
instructed to revisit within 14 days to repeat the test
in order to reduce the false-negative rate. The results
of methylene blue dye staining were recorded with
photographs, and biopsy was performed simultane-
ously in the suspected lesions to compare the accuracy
of the diagnostic capability of methylene blue.
Biopsy
Incision biopsy was performed in the most obvious
staining area of the suspicious lesion of patients under
local anesthesia. If there was no dye uptake in the
lesions, the biopsy specimen was taken from the area
judged by a specialist’s experience. The specimens
were then fixed in 10% neutral buffered formalin and
processed in the pathology laboratory for initial rou-
tine pathologic diagnosis.
Histologic examination
All the specimens were microscopically evaluated by
pathologists who were blind to the results of methyl-
ene blue stain. The pathology reports of the lesions
were classified as: (1) benign lesions including epithelial
hyperplasia, lichen planus, hyperkeratosis; (2) precancer-
ous lesions including verrucous hyperplasia, dysplasia;
and (3) malignant lesions including verrucous carci-
noma and squamous cell carcinoma.
Data analysis
The pathologically proven cancers and precancerous
lesions were the targets of screening. The results of
positive/negative uptake of methylene blue in each
lesion were correlated with the histopathologic diag-
nosis. Statistical analysis was performed, including sensi-
tivity, specificity, positive and negative predictive values.
The association of methylene blue uptake and patho-
logic diagnosis among the precancer/cancer group,
benign group, and normal group were analyzed using
Fisher’s exact test. A p value of less than 0.05 was
considered significant.
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Results
Subject characteristics
Seventy-eight people (58 patients, 20 students who
volunteered) were enrolled in this study. The patients’
ages (patient group) ranged from 31 to 82 years
(41 ± 15 years), with the ratio of male to female being
51:7. The students’ ages (control group) ranged from
20 to 24 years. Two-thirds of patients (n=38) had a
history of betel quid chewing, and 52 patients had a his-
tory of cigarette smoking. The suspected lesions were
distributed over the buccal mucosa (n = 25), tongue
(n=16), gingivae (n=9), lip (n=3), floor of the mouth
(n=2), palate (n=2), and retromolar trigone (n=1).
In the control group, as methylene blue dye was
not used to examine the oral cavity, it was necessary to
verify that the dye would not be retained on normal
mucosa. The results demonstrated that there was no
retained dye in the control group.
Methylene blue staining related to 
grade of pathology
The clinical and histopathologic diagnosis of oral
lesions and the results of staining are shown in Table 1.
The pathologic grade was classified as benign lesions,
precancer lesions and cancer lesions as previously
described in the methods section. The following sta-
tistical terms were used to describe and analyze the
relationship between the grade of pathology and the
uptake of methylene blue staining.
Sensitivity represents the proportion of histologi-
cally proved cancer/precancerous lesions which are
detected by positive methylene blue staining. In the
current study, 26 of 29 pathologically proved cancer/
precancerous lesions were positive with deep and focal
methylene blue staining (Figure 1B). The overall sen-
sitivity was 90%. Among the 3 false negative cases,
2 were clinically presented as chronic ulcers with indura-
tion over the tongue and were later proved as squamous
cell carcinoma after biopsy, and 1 was a homogeneous
leukoplakia on the buccal mucosa with a pathologic
diagnosis of epithelial dysplasia. They were stained
with a faint blue color (Figure 2B).
Specificity suggests the proportion of pathologic
benign lesions, neither precancerous lesions nor can-
cers, which are correctly identified as negative staining
of methylene blue (Figure 3B). In our study, 20 of 29
benign lesions showed negative staining; thus, the
specificity was 69%.
The results of staining with methylene blue for all
lesions correlated well with the pathologic diagnosis
and are summarized in Table 2. Fisher’s exact test
showed significant differences among cancer/precan-
cerous lesions, benign lesions, and normal control
groups (p < 0.05). Overall, the positive predictive value
was 74% (26/35), and the false predictive value was
87% (20/23).
Discussion
Oral cancer is very common in Southeast Asia, includ-
ing Taiwan. Areca nut chewing is the main etiologic fac-
tor inducing carcinogenesis in oral mucosa. Individuals
with all the habits of smoking, drinking and areca nut
chewing were reported to have 123 times the risk of
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Table 1. Clinical and histologic diagnosis of oral lesions and results of staining
Clinical diagnosis
Homogeneous Nonhomogeneous 
Erythroplakia Ulcerations
leukoplakia leukoplakia
(n = 5) (n = 6)
(n = 36) (n = 11)
Histologic diagnosis + – + – + – + –
Malignancy (n = 16)
Squamous cell carcinoma 10 – – – 3 – 1 2
Precancerous lesion (n = 13)
Dysplasia 4 – 3 – 1 – – –
Epithelial hyperplasia – 1 4 – – – – –
Benign lesion (n = 29)
Epithelial hyperplasia – 9 1 – – – – –
Hyperkeratosis – 2 3 – – – – –
Lichen planus 3 7 – – 1 – 1 2
Total (n = 58) 17 19 11 – 5 – 2 4
people without such habits.9 Thus, oral cancer screen-
ing of high-risk individuals is very important in these
countries.
For a large-scale community screen, some dye mate-
rials help to identify abnormal mucosa tissue which raise
oral examiners’ attention and refer the patients with
suspicious lesions to oral surgeons for further exami-
nations. This vital staining method was used at first in
medicine for detecting cervical dysplasia and carci-
noma in situ in the 1960s.10 Niebel and Chomet were
the pioneers who used dye material to detect oral can-
cer in 1964.11 Toluidine blue dye is known as 1 of the
diagnostic adjuncts to detect oral cancer/precancerous
lesions. The efficacy of this technique has been evalu-
ated in many reports with diverse results. It has yielded
sensitivities between 72% and 100%,5–8 and specifici-
ties between 45% and 67%, in detecting suspicious
malignancies. However, the Material Data Safety Sheet
indicates that toluidine blue is probably toxic by inges-
tion, and it is seldom used for detecting cancers in other
parts of the human body.
Methylene blue is another recently proposed dye
for in vivo staining used in endoscopic examination.
Its application has been reported recently in detecting
some gastrointestinal abnormalities such as Barrett’s
esophagus,12–14 gastric cancer,15 prostate cancers,16,17
and also bladder cancer.18 The exact mechanism for the
uptake of methylene blue dye in epithelial cells is still
not very clear, but it resembles toluidine blue dye in its
acidophilic characteristic and may penetrate into cells
with an abnormal increase in nucleic acid, thus result-
ing in different uptake between normal and highly
dysplastic/malignant cells.
Usage of the methylene blue technique in detecting
oral cancer or precancerous lesions has not been re-
ported thus far. Among all the statistical values, sensitiv-
ity rate and false-negatives are the most important in
evaluating the efficacy of certain diagnostic tools for
detecting abnormal lesions. In the current study, 26 of
29 pathology-proven precancer/cancer lesions showed
positive staining with deep and focal methylene blue
dye. Overall, 90% sensitivity (88% for malignancy and
92% for precancerous lesions) was reported, with a
false-negative rate of 10%. Compared to the 72–100%
sensitivity reported in the previous studies,5–8 these
values indicated that using methylene blue dye in the
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Figure 1. Presentation of a true-positive staining white
ulcerative lesion over the left buccal mucosa. (A) The lesion
presented clinically as a deep ulcer with induration. (B) Vital
staining with methylene blue showed deep and focal stain in
the lesion. (C) The final pathology revealed a moderately dif-
ferentiated squamous cell carcinoma. (Hematoxylin & eosin,
original magnification 100×).
detection of cancer or precancerous lesions is acceptable.
As for false-negatives, we consider that the ambiguous
light blue stains which may be misinterpreted as nega-
tive but clinically suspicious of malignancy still need
further biopsy to prove the diagnosis pathologically.
In the aspect of specificity, we obtained a value of
69% (20/29) with a resulting false-positive rate of 31%.
The 9 false-positives were homogeneous leukoplakia
(n=3), nonhomogeneous leukoplakia (n=4), erythro-
plakia (n = 1), and an ulceration (n = 1). The high
false-positive rate was discussed to be related to the
retention of stain in inflamed and trauma areas.19 Other
causative factors may include the irregular, papillary or
digital surfaces of the lesions, which may cause the
mechanical retention of dye, contamination of saliva
and plaque, retention of dye material in papilla of the
tongue or minor salivary gland ducts over the mucosa.
The high number of false-positives in this study means
that more patients received biopsies. Nevertheless,
rational management for patients with suspected oral
lesions who have either a positive or negative methyl-
ene blue stain remains biopsy of the lesion.
Applying this method to screen high-risk patients
with the habits of betel quid chewing or smoking, a
large group of individuals may include those with
obvious oral lesions and those with normal oral mucosa.
To study these people and to re-evaluate the efficacy of
methylene blue in detecting oral cancers/precancerous
lesions, a large proportion of the people with normal
oral mucosa will lower the rate of false-positives and
result in higher specificity. Although we had a control
group with fully normal oral mucosa, there was a flaw
in the experimental design that these students had no
habits of betel quid chewing and histories of smoking.
However, individuals who had these habits without
lesions were also not very suitable to be our control
group because performance of biopsy in normal mucosa
would not be ethical.
In conclusion, this study shows that methylene blue
staining has nearly 90% sensitivity in detecting oral
cancers or precancerous lesions. Considering its low
toxicity and the fact that it is cheaper than toluidine
blue, it may be convenient to substitute it for tolui-
dine blue in large-scale oral screening of high-risk
J Chin Med Assoc • November 2007 • Vol 70 • No 11 501
Methylene blue in detecting oral cancer and precancer
A B
C
Figure 2. Presentation of a false-negative staining white
lesion at the right tongue border. (A) The lesion (arrow) pre-
sented with an ulcerative surface with induration in the
deep base and peripheral area. (B) Vital staining with methyl-
ene blue showed faint blue stains over most of the lesion. (C)
Pathologic diagnosis revealed the lesion to be moderately dif-
ferentiated squamous cell carcinoma. (Hematoxylin &
eosin, original magnification 200×).
patients. Nevertheless, the pathology report from
biopsy is still the gold standard to accurately diagnose
the lesion before a treatment modality is determined.
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